|Ms. Lori A. Holmes-Woods||CEO & Director||371.19k||N/A||1962|
|Ms. Jennifer Streeter||COO & VP of HR||266.35k||N/A||1970|
|Mr. William A. Cavanagh III||Chief R&D Officer||253.34k||N/A||1966|
|Mr. Jonathan R. Hunt||CFO & Co-Principal Financial Officer||N/A||N/A||1967|
|Mr. Mark J. Austin CPA||VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.||N/A||N/A||1987|
|Ms. Krista Cline||Sr. Director of Operations & Corp. Sec.||N/A||N/A||1982|
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Isoray, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.